Bailard Inc. Has $854,000 Stake in Immunomedics, Inc. (IMMU)

Share on StockTwits

Bailard Inc. cut its stake in Immunomedics, Inc. (NASDAQ:IMMU) by 49.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,000 shares of the biopharmaceutical company’s stock after selling 39,500 shares during the quarter. Bailard Inc.’s holdings in Immunomedics were worth $854,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. First Allied Advisory Services Inc. purchased a new stake in shares of Immunomedics in the second quarter worth approximately $205,000. Jasper Ridge Partners L.P. purchased a new stake in shares of Immunomedics during the second quarter valued at approximately $259,000. Gideon Capital Advisors Inc. purchased a new stake in shares of Immunomedics during the third quarter valued at approximately $229,000. Trexquant Investment LP purchased a new stake in shares of Immunomedics during the second quarter valued at approximately $298,000. Finally, Parametrica Management Ltd purchased a new stake in shares of Immunomedics during the third quarter valued at approximately $281,000. 77.26% of the stock is owned by hedge funds and other institutional investors.

Shares of IMMU opened at $17.57 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. Immunomedics, Inc. has a 12 month low of $11.36 and a 12 month high of $27.33. The company has a market cap of $3.58 billion, a P/E ratio of -17.06 and a beta of 1.87.

Immunomedics (NASDAQ:IMMU) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same period in the previous year, the company earned ($0.97) earnings per share. On average, equities research analysts predict that Immunomedics, Inc. will post -1.2 EPS for the current year.

A number of analysts recently commented on the company. Goldman Sachs Group assumed coverage on Immunomedics in a research report on Monday, September 17th. They set a “buy” rating and a $36.00 price target for the company. BidaskClub downgraded Immunomedics from a “hold” rating to a “sell” rating in a research report on Friday, November 16th. B. Riley increased their price target on Immunomedics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, August 24th. Guggenheim assumed coverage on Immunomedics in a research report on Tuesday, September 18th. They set a “buy” rating and a $33.00 price target for the company. Finally, Morgan Stanley assumed coverage on Immunomedics in a research report on Monday, November 5th. They set an “overweight” rating and a $38.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Immunomedics presently has an average rating of “Buy” and a consensus price target of $38.43.

TRADEMARK VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/12/08/bailard-inc-has-854000-stake-in-immunomedics-inc-immu/3063886.html.

Immunomedics Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: Quiet Period

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.